Mirabella Financial Services LLP Raises Holdings in Johnson & Johnson $JNJ

Mirabella Financial Services LLP increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 150.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 14,161 shares of the company’s stock after purchasing an additional 8,501 shares during the period. Mirabella Financial Services LLP’s holdings in Johnson & Johnson were worth $2,621,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $4,877,174,000. Laurel Wealth Advisors LLC increased its holdings in Johnson & Johnson by 15,040.6% during the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after buying an additional 7,371,687 shares during the period. Capital International Investors raised its stake in Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock worth $716,657,000 after buying an additional 3,266,354 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares during the period. Finally, Amundi boosted its position in Johnson & Johnson by 19.3% during the 3rd quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after acquiring an additional 2,163,838 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Argus boosted their price target on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Guggenheim lifted their target price on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. The Goldman Sachs Group reiterated a “buy” rating and issued a $250.00 target price on shares of Johnson & Johnson in a report on Thursday, January 22nd. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Finally, Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $235.91.

Johnson & Johnson Stock Up 0.6%

Shares of JNJ stock opened at $243.03 on Tuesday. The stock’s fifty day moving average price is $232.69 and its 200 day moving average price is $207.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71. The company has a market cap of $585.37 billion, a price-to-earnings ratio of 21.99, a price-to-earnings-growth ratio of 2.38 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.